Activity in Biological Technology

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

REDWOOD CITY, Calif.,, Aug. 6 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the publication in Cell Stem Cell of data demonstrating potent anti-cancer activity in colon ...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

PRINCETON, N.J., June 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that new clinical and preclinical data demonstrating the extended therapeutic bioavailability and tumor cell selectivity of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in leukemia were presented at the 14th Co...

SemBioSys' plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models

CALGARY, May 19 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today reported encouraging data from the Company's Apo AI(Milano) development program. Results from recent preclinical studies show that SemBi...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

Results Will be Reported from Phase 2 Studies Evaluating KRX-0401 in Advanced Renal Cell Carcinoma, Colorectal Cancer and Gastrointestinal Stromal Tumors (GIST) NEW YORK, May 18 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that four abstracts on ...

ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.

FREDERICK, Md., March 31 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington...

Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain

BASEL, Switzerland, January 19 /PRNewswire-FirstCall/ -- - Tamiflu Remains Fully Effective Against 94 Percent of Circulating Influenza Viruses in Europe Latest surveillance data coming through the European Centre for Disease Prevention and Control (ECDC) from virologists and clin...

Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

Published in the Journal Blood for the American Society of Hematology Annual Meeting SOMERSET, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL ) today announced that American Society of Hematology (ASH) annual meeting abstracts in Blood (2008 112: Abstract 4...

Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium

Active metabolite concentrations of NKTR-102 significantly more sustained in between doses than possible with irinotecan GENEVA and SAN CARLOS, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported positive Phase 1 data for its lead proprietar...

Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist

-- Data Presented at 20th EORTC-NCI-AACR Symposium -- SEATTLE and GENEVA, Oct. 23 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN ) today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 (a transmembrane catio...

PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet

- One of the First Therapies to Address the Underlying Cause of Cystic Fibrosis; Oral Drug May Represent New Treatment Paradigm - SOUTH PLAINFIELD, N.J., Aug. 20 /PRNewswire/ -- New phase 2 data published today in The Lancet show that the investigational oral drug PTC124 demonstrates activit...

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer

SAN MARINO, Calif., May 19 /PRNewswire/ -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lo...

Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial

More than 90% of CIA patients treated with PBI-1402 did not require blood transfusion. MONTREAL, April 23 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces that oral PBI-1402 demonstrates significant activity in patients with che...

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

-- Lead NNRTI RDEA806 to begin Phase 2b trial in the second quarter of 2008 -- MONTREAL and SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data was presented on the Company's next generatio...

Experiments reveal unexpected activity of fuel cell catalysts

UPTON, NY -- Researchers at the U.S. Department of Energys Brookhaven National Laboratory have unveiled important details about a class of catalysts that could help improve the performance of fuel cells. With the goal of producing clean hydrogen for fuel cell reactions in mind, the researchers det...

Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers

Targeting tumor's vulnerability yields durable responses in Phase I/II Trial SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX), announced that cumulative prelim...

ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests

ADVENTRX Presents Results at 2007 AACR-NCI-EORTC International Conference SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment o...

Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

SEATTLE, Aug. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN ) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the saf...

UMass Boston Opens Venture Development Center to Expand R&D Activity

Facility to Foster Faculty and Student Research, Partnering with Industry Boston (Vocus) May 1, 2009 -- The University of Massachusetts Boston today officially opened a cutting-edge Venture Development Center that will significantly expand the university's research ...

TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity

JACKSONVILLE, Fla., March 16 /PRNewswire/ -- TauTaTis, Inc. announces that its lead compound for inhibition of tau protein pathology, the specific neurodegenerative process in Alzheimer's Disease, has been recognized as the most potent inhibitor of the activity of the Parkinson's Disease gene LRRK...

Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity

GENEVA, Switzerland, March 10 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced that ANAVEX 7-1037 has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies. T...

Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity

Promising pre-clinical results support advance to clinical study for third combination chemotherapy from Celator based on the company's proprietary CombiPlex(TM) technology platform. PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced positive re...

MoneyTree Survey reports no venture investment activity in Wisconin in Q2

MADISONThe recently released Q2 MoneyTree Survey figures show no reported venture investment activity in Wisconsin between April and June of this year. Both total venture capital and initial venture investments were reported in the survey, which was released by PricewaterhouseCoopers, Thomson Ventu...

Homogeneous, chemiluminescent kinase assay kits for assessing the functional activity of a broad range of serine-threonine and tyrosine kinases

J. Turner GE Healthcare, The Maynard Centre, Cardiff, UK Competitive binding assays have been developed for measuring the functional activity of a range of serine-threonine and tyrosine kinases. Based on enzyme fragment complementation and the ...

Detection of Reporter Gene Activity in Cell Cultures and Murine Epidermis After Helios Gene Gun-Mediated Particle Bombardment

Andreas Henke and Eunike Grohmann, Institute of Virology, Medical Center, Friedrich Schiller University Jena, Winzerlaer Str. 10, 07745 Jena, Germany Summary The Helios gene gun-mediated DNA transfer can be used as a fast and efficient method to trans...

RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control

Protecting RNA During Isolation RNase activity varies dramatically across different tissues. A comparison of total RNase activities for 8 different mouse tissues showed that total RNase activity spans a 181,000-fold range from pancreas t...

Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells

Prevalence and Roles of miRNAs More than 200 miRNAs have been cloned and sequenced from human and mouse samples. Each miRNA apparently regulates multiple genes, and miRNAs are thought to r...

Measuring RNase Activity A Real-time Kinetic Analysis

The RNaseAlert QC System, when used in conjunction with a fluorometer capable of kinetic analysis, provides a rapid and ultra-sensitive assay for determining RNase A specific activity. The RNaseAlert QC System also detects a variety of other ...

Increase Protein Activity and Yield

ActivePro In Vitro Translation Kit Higher yields of protein than reticulocyte lysate systems Fully compatible with eukaryotic protein translation Higher biological activity than other E. coli ...

Metavante Corp. will continue M&A activity

Milwaukee, Wis. Metavante Corp. , a provider of banking and payment technology, plans to continue its growth-by-acquisition strategy following its separation from long-time parent company Marshall & Illsley Corp. Metavante, a wholly owned subsidiary of M&I, has completed 17 acquisitions si...

Fluorescence assay for determination of protease activity

In research and industrial work it is quite often necessary to test whether samples or solutions are free of protease activity. Using commercially available kits e.g. from Molecular Probes Inc., protease activity can be measured with the new fluorometer from PerkinElmer Life Sciences, VIC...

Translate More Protein with Higher Biological Activity

ActivePro In Vitro Translation Kit Fully compatible with eukaryotic protein translation Better yields and faster translation than traditional reticulocyte ...

Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services

...overy process, researchers work at the molecular level to perform structure activity relationship (SAR) studies, seeking molecular patterns that may exhibit enhanced biological activity against disease targets. This virtual discovery process typically leads to ...

ThermoGenesis Provides Update on Fiscal 2009 Results

...tors are expected to drive growth and contribute to improved financial performance for the Company in fiscal 2010: Solid stem cell collection activity at our largest private cord blood banking customer, Cord Blood Registry ("CBR"). CBR expects these positive trends to continue during 2010. R...

OncoGenex Reports Second Quarter 2009 Financial Results

...ted as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation. - The Company reached an agreement with the U.S. Food and Drug Administration (FDA) via...

PDI Reports 2009 Second Quarter Financial Results

...ting Services segment, as it was for similar companies across the industry. However, over the second half of the year, we expect to see an upswing in activity and we remain optimistic about the opportunity for this business segment going forward." Financial Overview - Second Quarter 2009 ...

TSH Testing Raises Awareness of Importance of Thyroid Health

...y studied the effects of Iodine 131." "No single blood test can determine thyroid cancer but a TSH test may be used to evaluate the thyroid's activity and test for hypothyroidism, a disease that affects almost 30 million Americans. If this common form of thyroid disease is not detected and treated, i...

BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing

...lished to let shareholders know how BioNeutral's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Bio...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

...icacy across all three doses, with clinical cure rates in the clinically evaluable population ranging from 78% to 92%. Radezolid also showed excellent activity against a number of key CAP pathogens including Streptococcus pneumoniae, methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae and ...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

... Oncology (ASCO) Annual Meeting. The results continue to support picoplatin as a neuropathy-sparing alternative to oxaliplatin with similar anti-tumor activity as assessed by PFS and disease control measured by tumor response rate. New data derived by three independent assessments indicated a statistically s...

Micromet Closes $80.5 Million Public Offering of Common Stock

... TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune...